Danish created Victoza, which, in its 3rd phase of clinical trials, is shown to help those who are obese and/or Type 2 Diabetic lose weight.
When given in three mg doses over a a 1 year period, trial participants lost nearly 6% of their Body Weight.
“According to Dr. Maria Collazo-Clavel, an associate professor at College of Medicine, Mayo Clinic and medical editor of diabetes content on Mayo’s health information website and for “Mayo Clinic The Essential Diabetes Book,” the drug works mainly by suppressing appetite.
This method works because the drug delays the passage of food from the stomach to the small intestine, increasing the amount of time in which the patient is satiated.
If approved for use as a weight loss medication, the drug could serve an important patient group.”
Victoza is a relatively recently developed diabetes drug. Victoza (liraglutide) is a GLP-1 analogue for the treatment of type 2 diabetes.
Recently approved in the USA by the Food and Drug Administration and in Europe by the EU, the diabetes drug operates with a 24-hour duration of action, meaning that a single injection is all that is required.
The type 2 diabetes drug has now been approved and is being prescribed for people with type 2 diabetes in the UK.